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Abstract
Background:  Several trials from different populations have reported that non-high density
lipoprotein cholesterol (non-HDL-C) has more predictive power than low-density lipoprotein
cholesterol (LDL-C) in detecting coronary heart disease (CHD) and none in any Arab community
whose propensity to develop CHD is higher compared to other ethnicities. This study aims to
determine and compare the impact of non-HDL-C versus other lipid parameters, in predicting
coronary heart disease among diabetic versus non-diabetic adult Saudis and identify the lipid
parameters which make a significant contribution in the development of coronary heart disease,
diabetes mellitus, and metabolic syndrome. 733 adult Saudis were recruited and divided into groups
of diabetics and non-diabetics. Each participant completed a questionnaire, underwent physical
exam including 12-L ECG, and submitted a fasting blood sample where glucose and lipid parameters
were analyzed using routine procedures.
Results: 462 subjects (age 45.03 ± 11.52; BMI 28.91 ± 6.07) were classified non-diabetics while the
remaining 271 (age 52.73 ± 11.45, BMI 30.15 ± 6.62) were diabetics. 99 out of 465 (21.3%) of non-
diabetics had CHD and 114 out of 271 (52.5%) in the diabetics. Non-HDL cholesterol was the best
predictor among the non-diabetics (odds-ratio 2.89, CI 1.10–7.58, p-0.03). Total cholesterol was
the highest single predictor for the development of CHD among the lipids (odds-ratio 1.36, CI
0.68–2.71, p-0.39) but HDL-cholesterol although small was significant (odds-ratio 0.52, CI 0.27–
0.99, p-0.05).
Conclusion: This study supports the use of non-HDL cholesterol as the more practical and
reliable target for lipid lowering therapy among the Saudi population.
Background
It is apparent that atherosclerosis manifested by coronary
heart disease (CHD) is not only the single most common
cause of death among middle-aged people in industrial-
ized nations, but it is also the leading cause of morbidity
and mortality among people suffering from diabetes mel-
litus. Coronary heart disease and diabetes mellitus (DM)
are both chronic metabolic diseases whose pathophysiol-
ogy remains extremely complex and multi-factorial. Yet of
the many risk factors to blame, much attention has
Published: 4 April 2007
Lipids in Health and Disease 2007, 6:9 doi:10.1186/1476-511X-6-9
Received: 28 January 2007
Accepted: 4 April 2007
This article is available from: http://www.lipidworld.com/content/6/1/9
© 2007 Al-Daghri et al; licensee BioMed Central Ltd. 
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.Lipids in Health and Disease 2007, 6:9 http://www.lipidworld.com/content/6/1/9
Page 2 of 6
(page number not for citation purposes)
focused on the elevated lipid profile and its "atherogenic
potential" as a very powerful risk factor for the aggrava-
tion of these diseases. In the recent report of the expert
panel from the National Cholesterol Education Program
(NCEP) on detection, evaluation and treatment of high
blood cholesterol in adults (Adult Treatment Panel III),
they continued to recognize low-density lipoprotein cho-
lesterol (LDL-C) as the primary target for cholesterol low-
ering therapy [1]. This was of course based on the premise
that keeping lipid parameters to their optimal levels
would be certain to lessen the chances of developing cor-
onary heart disease.
Emerging novel risk factors were nevertheless recognized
by NCEP. One of them is the non-high density lipopro-
tein cholesterol (non-HDL-C), whose value can be calcu-
lated by subtracting HDL-cholesterol from the total
cholesterol. While several trials from different popula-
tions have reported that non-HDL-C has more predictive
power than LDL-C in detecting CHD [2,3], no such trials
have so far been made in any Arab community whose pro-
pensity to develop coronary heart disease is high com-
pared to other ethnicities [4]. Hence, this study primarily
aims to determine and compare the power and influence
of the novel risk factor non-HDL- cholesterol versus other
lipid parameters, in predicting coronary heart disease
among diabetic versus non-diabetic adult Saudis. This
study will also attempt to identify which among the lipid
parameters makes a significant contribution in the devel-
opment of coronary heart disease, diabetes mellitus, and
metabolic syndrome in the same population.
Results
From the sample population, 462 (age 45.03 ± 11.52; BMI
28.91 ± 6.07) were classified as non-diabetic, while the
remaining 271 (age 52.73 ± 11.45, BMI 30.15 ± 6.62)
were categorized as diabetic.
Table 1 reveals the clinical and metabolic characteristics of
both groups. It is apparent that the diabetics were signifi-
cantly older and fatter, with a higher blood pressure and
elevated lipid profile, except for HDL-cholesterol, than
the non-diabetic group. Only LDL-cholesterol was non-
significant.
In stepwise regression, triglycerides (R2 0.12, p-0.000) and
HDL-cholesterol (R2 0.13 p-0.003) had the significant
contribution when diabetes mellitus was regarded as the
dependent variable. Triglyceride was also the dominant
lipid (R2 0.007, p-0.03) in coronary heart disease. At the
same time, metabolic syndrome as defined by NCEP
ATPIII had triglycerides, HDL-cholesterol and total cho-
lesterol as its significant contributors (R2 0.17, 0.22, 0.23,
p-value 0.000 respectively).
Table 2 shows that 99 out of 465 (21.3%) of non-diabet-
ics had CHD as opposed to 114 out of 271 (52.5%)
among the diabetics indicating diabetes as a very strong
independent risk factor for the development of CHD
among Saudis.
In general, the chances of developing coronary heart dis-
ease increase as individual lipid components increase in
both groups. Worth noting is the positive trend for HDL
cholesterol in which the relative risk of CHD was highest
at a ≥ 1.55 level among the diabetics [1.76 (0.56–5.47)].
In logistic regression analysis, the cut-off points used for
each lipid parameter were based on the values set by
NCEP ATP III, which they considered optimal. Thus, the
cut-off points were: ≥ 2.59 mmol/L (≥ 100 mg/dl) in LDL-
C, ≥ 3.35 mmol/L (≥ 130 mg/dl) for non-HDL-C, ≥ 1.69
mmol/L (≥ 150 mg/dl) in triglycerides and ≤ 1.03 mmol/
L (≤ 40 mg/dl) in HDL-C and ≥ 5.17 mmol/L (≥ 200 mg/
dl) in total cholesterol. Clearly the non-HDL cholesterol
was the best predictor among the non-diabetics (odds-
ratio 2.89, CI 1.10–7.58, p-0.03) (see Table 3). In the dia-
betics group, total cholesterol was the highest single pre-
dictor for the development of CHD among the lipids
(odds-ratio 1.36, CI 0.68–2.71, p-0.39) but HDL-choles-
terol has a small but significant effect (odds-ratio 0.52, CI
0.27–0.99, p-0.05) (see Table 4).
Discussion
Grundy, in a recent report, emphasizes that there has to be
strong evidence of superiority for non-HDL cholesterol to
be regarded as the primary target of lipid therapy [6].
Since then, clinical trials all over the world have made fur-
ther contributions in the challenge to discover whether
non-HDL cholesterol is indeed superior to the incumbent
LDL cholesterol as the primary target of lipid-lowering
therapy [7-10]. This study can be regarded as contributing
to this growing evidence, using Saudis as the first subjects
to be considered in the Arab population as a whole.
The superiority of non-HDL cholesterol over LDL-choles-
terol started from a comparison of equations; non-HDL
cholesterol is a simple subtraction while LDL-cholesterol
is derived from 3 different analytes, with a conversion fac-
tor assumption. From a practical point of view, it is easier
and faster to compute for non-HDL cholesterol not to
mention the unreliability of LDL-cholesterol values when
≥ 400 mg/dl of serum triglycerides is reached [11]. Argua-
bly, LDL cholesterol remains to be the major player in
atherogenesis, but, when inaccuracy sets in, the validity of
clinical management will also be open to question. Sev-
eral studies support the view that non-HDL cholesterol
and apo B are superior to LDL cholesterol, especially
among diabetics whose triglyceride levels exceed the accu-Lipids in Health and Disease 2007, 6:9 http://www.lipidworld.com/content/6/1/9
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racy limit of the Friedewald formula for LDL-cholesterol
[11,12].
A study by Liu and his colleagues concludes that non-HDL
cholesterol is a stronger predictor of CHD death among
those with diabetes than among those with LDL choles-
terol and should be given more consideration in the clin-
ical approach to risk reduction among diabetic patients
[8]. Contrary to their findings, our study suggests non-
HDL as a stronger predictor among non-diabetics rather
than diabetics, in terms of developing CHD. The differ-
ence in results can be explained by several factors. First
among these factors is the choice of dependent variable
and the number of samples used; their study utilized CHD
death as the dependent variable with 19,381 samples
while our study focused more on existing CHD as the
dependent variable with 733 samples. The great discrep-
ancy in sample size and the unequal distribution of non-
diabetics (462) to diabetics (271) in the present study
may also have contributed to the disagreement between
the findings. Nevertheless, the potential significance of
non-HDL as a clinical tool in the management of non-dia-
betic patients merits supplementary investigation. Fur-
thermore, in their report there is a negative association of
HDL with CHD, which is different from our results. This
could be explained by the fact that Arabs, Saudis in partic-
ular, have a lower prevalence of hypercholesterolemia
than do their American and European counterparts [13].
In addition, we also considered the younger population
used, together with the culture and lifestyle differences,
Table 1: Clinical and Metabolic characteristics of subjects
Variable Non-Diabetics Diabetics P-Value
N4 6 2 2 7 1
Age (years) 45.03 ± 11.52 52.73 ± 11.45 0.000
Systolic BP (mmHg) 120.57 ± 18.23 130.17 ± 19.74 0.000
Diastolic BP (mmHg) 78.15 ± 11.65 82.27 ± 10.71 0.000
BMI (kg/m2) 28.91 ± 6.07 30.15 ± 6.62 0.011
LDL (mmol/L) 3.63 ± 1.31 3.47 ± 1.55 0.17
HDL (mmol/L) 0.91 ± 0.45 0.80 ± 0.32 0.000
Non-HDL (mmol/L) 4.36 ± 1.47 4.67 ± 1.54 0.009
Total Cholesterol (mmol/Ll) 5.26 ± 1.39 5.52 ± 1.74 0.04
Triglycerides (mmol/L) 1.74 ± 1.06 2.63 ± 1.37 0.000
* Data are presented as mean ± SD; p-value significant at < 0.05
Table 2: Relative risk of probable coronary heart disease for various cut-off values of lipids
Non-Diabetic Diabetic
N4 6 5 2 7 1
Probable CHD 99 114
LDL cholesterol (mmol/L)
< 2.59 0.87 (0.70–1.09) 0.95 (0.86–1.05)
2.59–3.34 0.99 (0.76–1.30) 1.03 (0.91–1.17)
≥ 3.35 1.05 (0.92–1.19) 1.13 (0.91–1.39)
Non-HDL- cholesterol (mmol/L)
< 3.35 0.94 (0.85–1.04) 0.95 (0.74–1.22)
3.35–4.13 0.86 (0.67–1.09) 1.06 (0.93–1.21)
≥ 4.14 1.01 (0.92–1.11) 1.15 (0.93–1.42)
Total Cholesterol (mmol/L)
< 5.17 1.02 (0.93–1.12 0.81 (0.65–1.00)
5.17–6.19 0.93 (0.84–1.03) 1.11 (0.86–1.44)
≥ 6.20 1.09 (0.95–1.24) 1.18 (0.91–1.53)
HDL Cholesterol (mg/dl)
≥ 1.55 0.85 (0.76–0.96) 1.76 (0.56–5.47)
1.03–1.54 1.10 (0.96–1.25) 1.37 (0.98–1.91)
< 1.03 0.99 (0.89–1.10) 0.70 (0.51–0.97)
Triglycerides (mg/dl)
< 1.69 0.79 (0.70–0.89) 0.96 (0.75–1.23)
1.69–2.25 0.98 (0.86–1.11) 1.20 (0.86–1.67)
≥ 2.26 1.05 (0.93–1.19) 0.94 (0.75–1.46)
*Data presented as Relative risk (95% Confidence interval)Lipids in Health and Disease 2007, 6:9 http://www.lipidworld.com/content/6/1/9
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one of which is the total prohibition of alcoholic bever-
ages in the Kingdom, which can greatly alter the lipid and
coagulation profiles of the subjects used [14,15]. As evi-
denced by the results of this study, decreased HDL-choles-
terol levels may not be as powerful as the rest of their lipid
counterparts when it comes to predicting CHD, but its
contribution to the progression of diabetes mellitus and
metabolic syndrome in the Saudi population is neverthe-
less equally important.
In our study, elevated triglycerides were the consistent sin-
gle significant contributor to the development of CHD,
diabetes mellitus and metabolic syndrome among the rest
of the lipid sub-components. While it is apparent that
hypertriglyceridemia is more closely linked to the constel-
lation of abnormalities which constitutes metabolic syn-
drome, the exact atherogenic properties of triglycerides
have been hard to explain, perhaps secondary to the
greater biologic variance than cholesterol [16]. Williams
and his colleagues report that elevated triglycerides is a
common abnormality in patients who had myocardial
infarction [17], while Benfante et.al confirm that triglycer-
ide value in those below 60 years was an independent pre-
dictor of CHD, but not in older people [18]. The mean age
of our subjects fall within the cut-off set by the latter's
study, which probably explains why triglycerides played a
significant part in the pathogenesis of these chronic dis-
eases. The association of triglycerides with coronary heart
disease remains difficult to unravel. Elevated levels do not
necessarily indicate increased atherogenicity suggesting
that only certain components may be atherogenic or may
be associated with metabolic abnormalities which are
atherogenic [16].
This study measured the lipid profiles of non-diabetic and
diabetic Saudi subjects to assess the impact of individual
lipid parameters, as compared to non-HDL cholesterol, in
predicting coronary heart disease. Given the fact that non-
HDL cholesterol possesses all the atherogenic lipopro-
teins (VLDL, intermediate-density lipoprotein and LDL)
as opposed to LDL alone [8], the possibility that it is supe-
rior to LDL in CHD risk prediction is undoubtedly strong.
Coronary heart disease is the end product of a chronic
interplay of metabolic and environmental influences
requiring the element of time, which is not modifiable.
Early detection and intervention, therefore, using clini-
cally important parameters such as non-HDL cholesterol
are vital to overall success in the management of CHD.
This study acknowledges some limitations. The significant
age gap in this study aside from the co-existing morbidity
which is diabetes, has undoubtedly contributed much of
the difference in relative risks of both the non-diabetic
and diabetic subjects. Other confounding factors in the
development of CHD which were not controlled in this
study, such as smoking, the presence of hypertension,
obesity, gender and family history warrant additional
investigation. Nevertheless, this study acknowledges the
Table 3: Logistic regression analysis using probable CHD as a dependent variable and the various lipids as independent variables
Non-Diabetics
Predictor β SE Odds-Ratio 95% Confidence 
Interval
P-Value
Non-HDL 1.06 0.49 2.89 1.10–7.58 0.03
HDL -0.19 0.27 0.83 0.49–1.40 0.48
LDL -0.65 0.48 0.52 0.21–1.32 0.17
Triglycerides 0.07 0.25 1.07 0.65–1.76 0.79
Total Cholesterol -0.36 0.29 0.69 0.39–1.23 0.21
β – Beta; SE – standard error
Table 4: Logistic regression analysis using probable CHD as a dependent variable and the various lipids as independent variables
Diabetics
Predictor β SE Odds-Ratio 95% Confidence Interval P-Value
Non-HDL -0.26 0.51 0.77 0.28–2.01 0.61
HDL -0.66 0.33 0.52 0.27–0.99 0.05
LDL 0.16 0.47 1.18 0.47–2.93 0.73
Triglycerides 0.09 0.31 1.09 0.59–2.01 0.78
Total Cholesterol 0.31 0.35 1.36 0.68–2.71 0.39
β – Beta; SE – standard errorLipids in Health and Disease 2007, 6:9 http://www.lipidworld.com/content/6/1/9
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fact that lipids play an essential role in atherogenesis, and
that it is accelerated in patients with diabetes mellitus. It
is the authors' hope that this study will be of help in the
future assessment of international authorities such as
NCEP in acknowledging novel risk factors such as non-
HDL cholesterol as a potent risk factor which should be
emphasized in the prevention of coronary heart disease
through lipid lowering agents.
Conclusion
In summary, elevated non-HDL-cholesterol has the high-
est risk of CHD among non-diabetics while elevated total
cholesterol has the highest risk among the diabetics.
Hypertriglyceridemia is the common significant contribu-
tor for the development of CHD, DM and metabolic syn-
drome. This study supports the use of non-HDL
cholesterol as the more practical and reliable target of
lipid lowering therapy among the Saudi population.
Methods
A total of 733 adult Saudis who were attending the out-
patient department of the Diabetes Research Unit of King
Abdul-Aziz University Hospital, Riyadh, Kingdom of
Saudi Arabia were recruited in this prospective and cross-
sectional study, which was conducted in 2005. Each par-
ticipant was given a generalized questionnaire which
included personal information and past and present med-
ical history. They were subdivided into two groups: non-
diabetics and diabetics. Diagnosis of diabetes was estab-
lished if the patient had: 1) prior diagnosis of type 2 dia-
betes mellitus; 2) fasting plasma glucose (FPG) was > 7.0
mmol/L and/or if taking oral hypoglycemics or on insulin
therapy; 3) clinical manifestations of diabetes (polydip-
sia, polyphagia, polyuria) and/or 4 2-hour oral glucose
tolerance test (OGTT) ≥ 11.1 mmol/L for asymptomatic
patients with elevated FPG. Patients with unstable condi-
tions, such as poorly controlled diabetes with complica-
tions, were excluded. All participants underwent complete
physical examination, including blood pressure, height,
weight, waist and hip measurements. BMI was calculated
as weight in kilograms divided by height in squared
meters. They also submitted fasting blood samples the
lipid profiles of which were measured, including fasting
plasma glucose under routine laboratory procedures.
LDL-cholesterol was calculated using the Friedewald for-
mula [11] while non-HDL cholesterol was calculated by
the difference between total and HDL-cholesterol. 12-L
ECG was also given and CHD was diagnosed on the basis
of prior diagnosis, abnormal resting ECG (pathological
Q-waves, T-wave inversion, etc...) and/or a history of cor-
onary angiography [5]. Written consent and approval
were obtained prior to being included in the study. Ethical
approval was granted by the Ethics Committee of the Col-
lege of Medicine and Research center of King Saud Univer-
sity, Riyadh, Kingdom of Saudi Arabia, prior to the
research proper.
Metabolic syndrome
Each subject was screened for the presence of metabolic
syndrome based on the criteria set by NCEP ATPIII, which
required at least 3 risk factors for establishing diagnosis.
The following risk factors were considered: fasting plasma
glucose ≥ 110 mg/dl; blood pressure ≥ 130/85 mmHg or
on anti-hypertensive treatment; plasma triglycerides ≥ 1.7
mmol/L; plasma HDL cholesterol < 1.04 mmol/L in men
and < 1.3 mmol/L in women; and waist circumference ≥
102 cm in men and ≥ 88 cm in women. A total of 385 sub-
jects (52.5%) had metabolic syndrome; 183 of whom
were non-diabetics and 202 diabetics (not shown in
table).
Statistical analysis
SPSS version 11.5 (Chicago, Illinois) for Windows was
used for the statistical evaluation of the results obtained.
All data are presented as mean ± SD since all variables of
interest were normally distributed. An independent stu-
dent's t-test was used to compare the variables from both
groups. Relative risk was utilized to assess the probability
of acquiring possible coronary heart disease at different
levels of each lipid profile component. Logistic regression
analysis was used to assess risk for individual components
of the lipid profile among the diabetics and non-diabetics.
Stepwise linear regression was used to determine the con-
tribution of individual lipid parameters in the develop-
ment of diabetes, coronary heart disease and metabolic
syndrome.
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